<DOC>
	<DOCNO>NCT00110110</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin , etoposide , vincristine , work different way stop growth tumor cell , either kill cell stop dividing . Sometimes chemotherapy give , stop growth tumor cell . The tumor say resistant chemotherapy . Giving cyclosporine together chemotherapy may reduce drug resistance allow tumor cell kill . Cryotherapy kill tumor cell freeze . Laser therapy use light kill tumor cell . Giving combination chemotherapy together cyclosporine follow cryotherapy and/or laser therapy may effective treatment retinoblastoma . PURPOSE : This phase II trial study well give combination chemotherapy together cyclosporine follow cryotherapy and/or laser therapy work treat patient newly diagnose retinoblastoma eye .</brief_summary>
	<brief_title>Combination Chemotherapy Cyclosporine Followed Focal Therapy Bilateral Retinoblastoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare efficacy neoadjuvant high-dose carboplatin etoposide , vincristine , cyclosporine ( CSA ) follow ophthalmic focal therapy comprise cryotherapy and/or laser therapy historical world data chemotherapy treatment without CSA , term increase proportion eye remain relapse free require external beam radiotherapy and/or enucleation , patient newly diagnose Group B , C , D bilateral intraocular retinoblastoma . Secondary - Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients receive high-dose carboplatin IV 30 minute day 1 ; vincristine IV 5 minute high-dose etoposide IV 25 minute day 2 ; cyclosporine IV 1 hour chemotherapy 2 hour chemotherapy day 1 2 , filgrastim ( G-CSF ) subcutaneously daily begin day 3 continue day 16 blood count recover . Treatment repeat every 21 day total 3 course patient Group B disease total 6 course patient Group C D disease . Patients undergo eye examination anesthesia ( EUA ) initial stag course chemotherapy . Patients small peripheral tumor eye without retinal detachment undergo minimal focal therapy ( mainly cryotherapy ) EUA initial stag chemotherapy course 1 2 . At EUA third subsequent course chemotherapy , patient tumor sufficiently reduce size undergo additional cryotherapy laser therapy . After completion chemotherapy , patient suspicious , active , reactivated tumor undergo additional cryotherapy and/or laser therapy EUA approximately every 4-8 week ( long interval ) 5 year ( need ) . After completion study chemotherapy , patient follow every 3 month 2 year , every 6 month 2 year , annually 1 year . PROJECTED ACCRUAL : A total 71 patient accrue study within 2.4 year .</detailed_description>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>&gt; &gt; INCLUSION CRITERIA &lt; &lt; DISEASE CHARACTERISTICS : Clinical diagnosis bilateral intraocular retinoblastoma ( RB ) International Intraocular Retinoblastoma Classification ( IIRC ) Group B , C , D disease 1 eye IIRC Group E disease 1 eye allow provide eye enucleate diagnosis AND extraocular RB enucleate eye histologic confirmation AND IIRC Group B , C , D disease remain eye PATIENT CHARACTERISTICS : Age Over 30 day Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic AST ALT &lt; 2 time upper limit normal ( ULN ) Conjugated unconjugated bilirubin &lt; 2 time ULN Renal Creatinine &lt; 1.5 time ULN Glomerular filtration rate ( GFR ) â‰¥ 100 mL/min* NOTE : *A 4hour IV hydration allow GFR low due poor hydration transient dehydration Other Meets 1 follow auditory criterion : Normal audiogram At least normal response speech audiogram Documentation hearing acoustic emission test Recording evoke potential auditory brain stem response PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery See Disease Characteristics &gt; &gt; EXCLUSION CRITERIA &lt; &lt; IIRC Group A disease 1 eye unilateral RB extraocular metastatic RB young 30 day Glomerular filtration rate ( GFR ) &lt; 100 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>intraocular retinoblastoma</keyword>
</DOC>